<DOC>
	<DOCNO>NCT00892190</DOCNO>
	<brief_summary>This open label , prospective , single institution dose-escalation study . The patient population include non-induction candidate elderly patient AML MDS and/or patient high-risk relapsed/refractory AML MDS . Five dose cohort evaluate use fix dose ATRA combination escalate dose dasatinib . The investigator treat escalate dose dasatinib 70mg 140mg daily . Dose escalation proceed standard 3+3 fashion . A de-escalation 50 mg total daily dose dasatinib plan DLT great equal 33 % observe first dose level . Once MTD combination drug establish , 6 additional patient enrol MTD level obtain additional safety information combination allow preliminary laboratory correlate analysis .</brief_summary>
	<brief_title>Study Dasatinib All-Trans Retinoic Acid Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndrome</brief_title>
	<detailed_description>Primary Objective : 1 . To determine safety tolerability combination dasatinib ATRA relapse elderly , non-induction candidate acute myelogenous leukemia ( AML ) MDS patient identify maximally tolerate dose ( MTD ) , dose-limiting toxicity ( DLT ) . Secondary Objectives : 1 . To determine pharmacokinetic ( PK ) profile dasatinib ATRA administer combination therapy patient AML MDS 2 . To determine combination therapy dasatinib ATRA promote differentiation AML MDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Inclusion Informed consent Performance Status ( ECOG ) less equal 3 Subjects age 18 older Confirmed diagnosis nonAPL AML ( WHO criteria ) highrisk MDS ( IPSS criterion INT2 High ) For subject Age &lt; 65 : Refractory AML AML relapse within six month attain remission AML relapse six month achieve remission , achieve second remission Untreated subject develop AML preexist hematologic disease Secondary AML highrisk MDS either candidate hypomethylating agent fail one hypomethylating agent For subject Age ≥65 : De novo AML candidate induction chemotherapy Refractory AML AML relapse within six month attain remission AML relapse six month achieve remission , achieve second remission Untreated subject develop AML preexist hematologic disease Secondary AML highrisk MDS either candidate hypomethylating agent fail one hypomethylating agent Life expectancy least 2 month Adequate Organ Function : Total bilirubin &lt; 2.0 time institutional Upper Limit Normal ( ULN ) , Hepatic enzyme ( AST , ALT ) ≤ 2.5 time institutional ULN , Serum Creatinine &lt; 2.0 time institutional ULN Ability take oral medication ( dasatinib must swallow whole ) Concomitant Medications : Patient agree discontinue St. Johns Wort receive dasatinib therapy ( discontinue St. Johns Wort least 5 day start dasatinib ) . Patient agree IV bisphosphonates withhold 4 week dasatinib therapy due risk hypocalcemia . Age Sex : Men woman , age 18100 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 30 day last dose study drug minimize risk pregnancy . WOCBP include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea last &gt; = 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum folliclestimulating hormone ( FSH ) level great 35 mIU/mL . Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg , vasectomy ) consider childbearing potential . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour start investigational product . A male subject father potential must use adequate method contraception avoid conception throughout study [ 30 day last dose study drug ] minimize risk pregnancy . A barrier method recommend . Exclusion : Sex Reproductive Status : WOCBP unwilling unable use acceptable method avoid pregnancy entire study period least 4 week last dose study drug . Women pregnant breastfeeding . Women positive pregnancy test . Sexually active fertile men use effective birth control partner WOCBP . Target Disease Exceptions : Subjects diagnosis Acute Promyelocytic Leukemia , Known clinically suspect CNS involvement , HIV Positivity , A diagnosis another active malignancy exception nonmelanoma skin cancer cervical cancer situ. , Gastrointestinal condition could affect drug absorption include post surgical state gastric bypass , History psychiatric disorder may compromise compliance , Stem cell transplant within 60 days. , Subjects undergone stem cell transplant undergoing treatment prophylaxis Graft versus host disease Medical History Concurrent Diseases : Concurrent medical condition may increase risk toxicity , include : Pleural pericardial effusion grade , Cardiac Symptoms ; follow consider exclusion : Uncontrolled angina , congestive heart failure MI within ( 6 month ) , Diagnosed congenital long QT syndrome , Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) , Prolonged QTc interval preentry electrocardiogram ( &gt; 470 msec ) , Subjects hypokalemia hypomagnesemia correct prior dasatinib administration Physical Laboratory Test Findings : Chronic diarrhea , Uncontrolled , lifethreatening infection respond antimicrobial therapy Allergies Adverse Drug Reactions : History allergic reaction ATRA , History allergic reaction dasatinib Prohibited Treatments and/or Therapies : Category I drug generally accept risk cause Torsades de Pointes prolonge QT interval include : ( Patients must discontinue drug 7 day prior start dasatinib ) ( See section 5.6.1.2 ) quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycin , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine , azithromycin , citalopram , escitalopram , flecainide , mesoridazine , sevoflurane . Potent inhibitor CYP3A4 ( see section 5.6.1.1 detail ) . Proton pump inhibitor H2 inhibitor ( see section 5.6.2.3 ) . St. John 's Wort ( see section 5.6.2.4 ) . Medications inhibit platelet function anticoagulant ( see section 5.6.2.5 ) . Currently receive anticancer therapy . Use hydroxyurea within 7 day prior screen lab . Treatment investigational agent within 30 day prior first dose dasatinib/ATRA plan receive investigational agent study . Growth factor within 14 day prior screen lab Other Prisoners , subject involuntarily incarcerate . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>trans retinoic acid</keyword>
	<keyword>relapse AML</keyword>
	<keyword>refractory AML</keyword>
	<keyword>Relapsed/Refractory Acute myelogenous leukemia</keyword>
	<keyword>Elderly subject ( age 65 old ) acute myelogenous leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>